Seven patients on AbbVie Inc.’s drugs for hepatitis C died after liver failure, prompting U.S. regulators to change their advice on how the medicine should be administered.
Doctors should monitor patients using Viekira Pak or Technivie for signs of worsening liver disease, the U.S. Food and Drug Administration said in a statement Thursday. The medication is AbbVie’s second-best selling drug.
